Stem cells treatment for fistulas in Crohn’s disease is about to be approved in Catalonia a

by Fundació Clínic per a la Recerca Biomèdica

Treatment with mesenchymal stem cells (MSCs), extracted from fat tissue, is a powerful tool for the cure of autoimmune diseases such as Crohn’s disease.

Read more

World Inflammatory Bowel Disease Day (ulcerative colitis)

by GoodGut

​Today is World Inflammatory Bowel Disease (IBD) Day; IBD is a set of chronic disorders of unknown cause affecting the gastrointestinal system in over 50 million people. The most common forms are Cr...

Read more

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

by TIGENIX SAU

Takeda Pharma AG (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced that the Swiss Agency for Therapeutic Products (Swi...

Read more

TiGenix Cx601 positive long-term results to be presented at digestive disease week

by TIGENIX SAU

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop nove...

Read more

TiGenix announces positive topline week-104 data for Cx601 ADMIRE-CD Trial

by TIGENIX SAU

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem ce...

Read more

Takeda and TiGenix report new data highlighting maintenance of long-term remission of complex perianal Fistulas in Crohn’s disease patients with Cx601

by TIGENIX SAU

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced new data from the Phase 3 ADMIRE-CD clinical trial, ...

Read more

TiGenix announces Orphan Drug Designation (ODD) for Cx601 in Switzerland

by TIGENIX SAU

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells...

Read more

Takeda and TiGenix Announce the Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

by TIGENIX SAU

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Dis...

Read more

Takeda and TiGenix enter into licensing agreement for Ex-U.S. rights to Cx601 for the treatment of complex perianal fistulas in patients with crohn’s disease

by TIGENIX SAU

​Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels: TIG) (“TiGenix”) today announced that the companies have entered into an exclusive ex-U.S. li...

Read more

A protein implicated in Crohn’s Disease predisposes the development of a type of lymphoma

by CIMA - Centro de Investigación Médica Aplicada

International research directed by CIMA of the University of Navarra suggests that inhibition of NKX2-3 may be a selective therapeutic strategy in marginal-zone lymphomagenesis

Read more

TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial

by TIGENIX SAU

These positive data allow for European filing in the first quarter of 2016 and moving forward in the US with the SPA1-approved pivotal study

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

More than 6% of Europeans suffer from de...

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

A study in 27 European countries led by researchers from King’s Coll...

Photos Stream